Cathelicidins Target HSP60 To Restrict CVB3 Transmission via Disrupting the Exosome and Reducing Cardiomyocyte Apoptosis

The relative mechanisms that cathelicidin antimicrobial peptides use to influence nonenveloped virus infection are unclear. We show here that cathelicidin antimicrobial peptides (CRAMP and LL-37) directly target exosomal HSP60 to destroy exosomes, which in turn block the diffusion of exosomes to recipient cardiomyocytes and reduced HSP60-induced apoptosis, thus restricting coxsackievirus B3 infection. ABSTRACT Cathelicidin antimicrobial peptides (mouse, CRAMP; human, LL-37) have broad-spectrum antiviral activities against enveloped viruses, but their mechanisms of action against nonenveloped viruses remain to be elucidated. Coxsackievirus B3 (CVB3), a member of nonenveloped virus belonging to the Enterovirus genus of Picornaviridae, is an important pathogen of viral myocarditis and dilated cardiomyopathy. Here, we observed that cardiac CRAMP expression was significantly upregulated in mice after CVB3 infection. The administration of CRAMP or LL-37 markedly suppressed CVB3 infection in mice, and CRAMP deficiency increased the susceptibility of mice to CVB3. CRAMP and LL-37 inhibited CVB3 replication in primary cardiomyocytes. However, they did not inactivate CVB3 particles and did not regulate the response of cardiomyocytes against CVB3 infection. Intriguingly, they inhibited CVB3 transmission through the exosome, but not virus receptor. In detail, CRAMP and LL-37 directly induced the lysis of exosomes by interfering with exosomal heat shock protein 60 (HSP60) and then blocked the diffusion of exosomes to recipient cells and inhibited the establishment of productive infection by exosomes. In addition, the interaction of CRAMP and LL-37 with HSP60 simultaneously inhibited HSP60-induced apoptosis in cardiomyocytes and reduced HSP60-enhanced CVB3 replication. Our findings reveal a novel mechanism of cathelicidins against viral infection and provide a new therapeutic strategy for CVB3-induced viral myocarditis. IMPORTANCE The relative mechanisms that cathelicidin antimicrobial peptides use to influence nonenveloped virus infection are unclear. We show here that cathelicidin antimicrobial peptides (CRAMP and LL-37) directly target exosomal HSP60 to destroy exosomes, which in turn block the diffusion of exosomes to recipient cardiomyocytes and reduced HSP60-induced apoptosis, thus restricting coxsackievirus B3 infection. Our results provide new insights into the mechanisms cathelicidin antimicrobial peptides use against viral infection.

[1]  Jing Wu,et al.  Endogenous cathelicidin is required for protection against ZIKV-caused testis damage via inactivating virons. , 2022, Antiviral research.

[2]  Wenjie Liang,et al.  Intestinal Cathelicidin Antimicrobial Peptide Shapes a Protective Neonatal Gut Microbiota against Pancreatic Autoimmunity. , 2021, Gastroenterology.

[3]  Yi Sun,et al.  Neddylation of Coro1a determines the fate of multivesicular bodies and biogenesis of extracellular vesicles , 2021, Journal of extracellular vesicles.

[4]  S. Xiong,et al.  Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection , 2021, Journal of Controlled Release.

[5]  W. Xu,et al.  Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding. , 2021, Antiviral research.

[6]  Yuan Luo,et al.  Kruppel-like factor 10 protects against acute viral myocarditis by negatively regulating cardiac MCP-1 expression , 2020, Cellular & Molecular Immunology.

[7]  P. Bruneval,et al.  Major 5′terminally deleted enterovirus populations modulate type I IFN response in acute myocarditis patients and in human cultured cardiomyocytes , 2020, Scientific Reports.

[8]  M. Costafreda,et al.  Exosome mimicry by an HAVCR1/NPC1 pathway of endosomal fusion mediates hepatitis A virus infection , 2020, Nature Microbiology.

[9]  Michael Zhuo Wang,et al.  Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis , 2019, Cells.

[10]  T. Lu,et al.  Human cathelicidin peptide LL‐37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections , 2019, Antiviral research.

[11]  F. Cui,et al.  Altered exosomal miR-181d and miR-30a related to the pathogenesis of CVB3 induced myocarditis by targeting SOCS3. , 2019, European review for medical and pharmacological sciences.

[12]  J. García-Cordero,et al.  Human keratinocyte cultures (HaCaT) can be infected by DENV, triggering innate immune responses that include IFNλ and LL37. , 2018, Immunobiology.

[13]  M. Safran,et al.  Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production , 2018, Molecular medicine.

[14]  J. Qiu,et al.  CVB3 Nonstructural 2A Protein Modulates SREBP1a Signaling via the MEK/ERK Pathway , 2018, Journal of Virology.

[15]  Jianfeng Dai,et al.  Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3 , 2018, PLoS pathogens.

[16]  Zhiwei Wu,et al.  Exosome-mediated miR-146a transfer suppresses type I interferon response and facilitates EV71 infection , 2017, PLoS pathogens.

[17]  C. Stevens,et al.  Cathelicidins display conserved direct antiviral activity towards rhinovirus , 2017, Peptides.

[18]  P. Shil,et al.  In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2 , 2017, Peptides.

[19]  J. McCullers,et al.  Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice. , 2016, Antiviral research.

[20]  M. Shiina,et al.  Antimicrobial peptide LL‐37 attenuates infection of hepatitis C virus , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[21]  B. García-Pérez,et al.  Expression of Antimicrobial Peptides in Human Monocytic Cells and Neutrophils in Response to Dengue Virus Type 2 , 2016, Intervirology.

[22]  Ke Zhang,et al.  A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses , 2016, Scientific Reports.

[23]  B. Böttcher,et al.  Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans , 2016, The Journal of Immunology.

[24]  R. Lai,et al.  Mitochondrial DNA-LL-37 Complex Promotes Atherosclerosis by Escaping from Autophagic Recognition. , 2015, Immunity.

[25]  Wei Xu,et al.  Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis. , 2015, Antiviral research.

[26]  P. van Endert,et al.  Pancreatic β-Cells Limit Autoimmune Diabetes via an Immunoregulatory Antimicrobial Peptide Expressed under the Influence of the Gut Microbiota. , 2015, Immunity.

[27]  Guangshun Wang,et al.  Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses , 2015, PloS one.

[28]  Jieyan Pan,et al.  Expression of Human Decay-Accelerating Factor on Intestinal Epithelium of Transgenic Mice Does Not Facilitate Infection by the Enteral Route , 2015, Journal of Virology.

[29]  A. Segall,et al.  Coxsackievirus B Exits the Host Cell in Shed Microvesicles Displaying Autophagosomal Markers , 2014, PLoS pathogens.

[30]  Derek Macmillan,et al.  The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus , 2013, PloS one.

[31]  Jeroen A. A. Demmers,et al.  Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells , 2013, Proceedings of the National Academy of Sciences.

[32]  Z. Malik,et al.  Cardiac myocyte exosomes: stability, HSP60, and proteomics. , 2013, American journal of physiology. Heart and circulatory physiology.

[33]  F. Hu,et al.  A pathogenic picornavirus acquires an envelope by hijacking cellular membranes , 2013, Nature.

[34]  Sandeep Sagar,et al.  Myocarditis , 2012, The Lancet.

[35]  R. Choi,et al.  HIV-Neutralizing Activity of Cationic Polypeptides in Cervicovaginal Secretions of Women in HIV-Serodiscordant Relationships , 2012, PloS one.

[36]  Elizabeth Delorme-Axford,et al.  The Coxsackievirus B 3Cpro Protease Cleaves MAVS and TRIF to Attenuate Host Type I Interferon and Apoptotic Signaling , 2011, PLoS pathogens.

[37]  H. Atkins,et al.  A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes , 2010, Peptides.

[38]  Se-Chan Kim,et al.  Extracellular Heat Shock Protein 60, Cardiac Myocytes, and Apoptosis , 2009, Circulation research.

[39]  G. Hunninghake,et al.  Respiratory Epithelial Cells Convert Inactive Vitamin D to Its Active Form: Potential Effects on Host Defense1 , 2008, The Journal of Immunology.

[40]  J. Söderlund,et al.  The antimicrobial peptide LL-37 inhibits HIV-1 replication. , 2007, Current HIV research.

[41]  A. Knowlton,et al.  HSP60 trafficking in adult cardiac myocytes: role of the exosomal pathway. , 2007, American journal of physiology. Heart and circulatory physiology.

[42]  R. Zell,et al.  Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3 , 2007, Apoptosis.

[43]  James F. Jones,et al.  Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. , 2006, Immunity.

[44]  Ling C. Huang,et al.  Human Cathelicidin (LL-37), a Multifunctional Peptide, is Expressed by Ocular Surface Epithelia and has Potent Antibacterial and Antiviral Activity , 2005, Current eye research.

[45]  V. Kytö,et al.  Glutathione depletion and cardiomyocyte apoptosis in viral myocarditis , 2004, European journal of clinical investigation.

[46]  James F. Jones,et al.  Selective Killing of Vaccinia Virus by LL-37: Implications for Eczema Vaccinatum1 , 2004, The Journal of Immunology.

[47]  M. Zasloff Antimicrobial peptides of multicellular organisms , 2002, Nature.

[48]  R. Bals,et al.  The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Kozak,et al.  Identification of CRAMP, a Cathelin-related Antimicrobial Peptide Expressed in the Embryonic and Adult Mouse* , 1997, The Journal of Biological Chemistry.

[50]  D. Davidson,et al.  Antiviral potential of cathelicidins. , 2014, Future microbiology.

[51]  K. Hartshorn,et al.  The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. , 2013, The Journal of general virology.

[52]  Manuel V. Hermenegildo,et al.  An Overview of , 2011 .

[53]  B. McManus,et al.  Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. , 1991, Laboratory investigation; a journal of technical methods and pathology.